The FIFARMA Time to Vax 2025, developed by FIFARMA in collaboration with IQVIA, is the first regional study to analyze access to and availability of innovative vaccines across twelve countries in Latin America. Based on a methodology inspired by the indicator of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the report evaluates 29 vaccines approved globally between 2010 and 2025, examining the time to local approval, levels of public and private availability, and the role of the Pan American Health Organization’s Revolving Fund. The study identifies progress, but also persistent gaps between approval and public coverage, contributing evidence to strengthen timely access to innovative vaccines in the region.